Human Nesidioblastosis Tissue as an Immunogen for Generation of Islet Cell Specific Monoclonal Antibodies

Gerbitz, Klaus-Dieter; Boenke, B; Paprotta, A.; Chemnitz, U.; Hübner, G

doi:10.1515/cclm.1988.26.11.659

Cited by 2 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Animal models (e.g., hamster, mouse, monkey) or distinct cell culture models of nesidioblastosis/islet cell hyperplasia/proliferation have mainly been developed in the context of regenerative treatments for diabetes mellitus, experimental pancreatitis, or in the study of pancreatic malignancies [ 340 , 341 , 342 , 364 , 372 , 373 , 374 , 375 , 376 , 377 , 378 , 379 , 380 , 381 , 382 , 383 , 384 , 385 , 386 , 387 ]. Due to a lack of significant contribution to the understanding of the pathophysiology of human nesidioblastosis, this is not further discussed here.…”

Section: Etiology and Pathophysiology Of Niphs/nesidioblastosis With ...mentioning

confidence: 99%

Diffuse, Adult-Onset Nesidioblastosis/Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS): Review of the Literature of a Rare Cause of Hyperinsulinemic Hypoglycemia

Dieterle,

Husari,

Prozmann

et al. 2023

Biomedicines

View full text Add to dashboard Cite

Differential diagnosis of hypoglycemia in the non-diabetic adult patient is complex and comprises various diseases, including endogenous hyperinsulinism caused by functional β-cell disorders. The latter is also designated as nesidioblastosis or non-insulinoma pancreatogenous hypoglycemia syndrome (NIPHS). Clinically, this rare disease presents with unspecific adrenergic and neuroglycopenic symptoms and is, therefore, often overlooked. A combination of careful clinical assessment, oral glucose tolerance testing, 72 h fasting, sectional and functional imaging, and invasive insulin measurements can lead to the correct diagnosis. Due to a lack of a pathophysiological understanding of the condition, conservative treatment options are limited and mostly ineffective. Therefore, nearly all patients currently undergo surgical resection of parts or the entire pancreas. Consequently, apart from faster diagnosis, more elaborate and less invasive treatment options are needed to relieve the patients from the dangerous and devastating symptoms. Based on a case of a 23-year-old man presenting with this disease in our department, we performed an extensive review of the medical literature dealing with this condition and herein presented a comprehensive discussion of this interesting disease, including all aspects from epidemiology to therapy.

show abstract

Section: Etiology and Pathophysiology Of Niphs/nesidioblastosis With ...mentioning

confidence: 99%

Diffuse, Adult-Onset Nesidioblastosis/Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS): Review of the Literature of a Rare Cause of Hyperinsulinemic Hypoglycemia

Dieterle,

Husari,

Prozmann

et al. 2023

Biomedicines

View full text Add to dashboard Cite

show abstract

“…The percentage of Nl-positive cells increased from 17 _+ 4 % to 83 + 6 %. This preparation enriched for endocrine cells allows future studies on possible endocrine precursor cells.Key words: Monoclonal antibody, human fetal pancreas, endocrine cells, flow cytometry, cell separation, differentiation.Several antibodies have been reported to react with Beta cells or endocrine pancreatic cells [1][2][3][4][5][6]. Rat Beta cells or :islets were usually the substrate when determining the specificity of these antibodies.…”

mentioning

confidence: 99%

Enrichment of Beta cells from the human fetal pancreas by fluorescence activated cell sorting with a new monoclonal antibody

et al. 1992

View full text Add to dashboard Cite

The aim of this study was to produce an antibody reactive to the surface of endocrine pancreatic cells and use this antibody for the purification of endocrine cells from the human fetal pancreas by fluorescence activated cell sorting. We describe such an antibody, called N1, reacting with the surface and cytoplasm of endocrine cells in the adult and fetal human pancreas (12 to 18 weeks gestational age). While unreactive to exocrine and mesenchymal cells, it was not specific for endocrine cells, as evidenced by its staining pattern in tissues other than pancreas. Almost 40% of the N1-positive pancreatic cells contained either insulin, glucagon or somatostatin. Conversely, more than 90% of each of the hormone-containing cells was N1 positive. An additional 40% of N1-positive cells, not containing other pancreatic hormones, was shown to contain islet amyloid polypeptide, synaptophysin, chromogranin, tyrosine hydroxylase or CA812. A two-step collagenase digestion protocol yielded 1.29 +/- 0.17 x 10(5) cells per mg pancreatic tissue. After Percoll gradient centrifugation, the suspension contained 15.6 +/- 5.7% (n = 25, mean +/- SD) cells reactive with N1. By fluorescence activated cell sorting using the antibody N1, the single-cell suspension was enriched from 3.0 +/- 1.4% to 16.2 +/- 4.8% (n = 10, p less than 0.01) Beta cells. Alpha and Delta cells were also enriched significantly by this procedure. The percentage of N1-positive cells increased from 17 +/- 4% to 83 +/- 6%. This preparation enriched for endocrine cells allows future studies on possible endocrine precursor cells.

show abstract

Human Nesidioblastosis Tissue as an Immunogen for Generation of Islet Cell Specific Monoclonal Antibodies

Cited by 2 publications

References 13 publications

Diffuse, Adult-Onset Nesidioblastosis/Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS): Review of the Literature of a Rare Cause of Hyperinsulinemic Hypoglycemia

Diffuse, Adult-Onset Nesidioblastosis/Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS): Review of the Literature of a Rare Cause of Hyperinsulinemic Hypoglycemia

Enrichment of Beta cells from the human fetal pancreas by fluorescence activated cell sorting with a new monoclonal antibody

Contact Info

Product

Resources

About